{
    "filename": "d41573-020-00016-0.pdf",
    "content_type": "application/pdf",
    "file_size": 597866,
    "metadata": {
        "identifiers": {
            "doi": "10.1038/d41573-020-00016-0",
            "arxiv": null,
            "isbn": null,
            "doc_id": null,
            "url": "https://media.nature.com/original/magazine-assets/d41573-020-00016-0/d41573-020-00016-0.pdf"
        },
        "title": "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)",
        "author": "Guangdi Li, Erik De Clercq",
        "date": 2020,
        "affiliations": [
            "Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.",
            "Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. \u2709e-mail: liguangdi.research@ gmail.com; erik.declercq@ kuleuven.be https://doi.org/10.1038/ d41573-020-00016-0"
        ],
        "journal": "Nature Reviews Drug Discovery",
        "volume": "19",
        "abstract": "Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.",
        "references": "@article{de2016a,\n  author = {De Clercq, E. and Li, G.},\n  title = {Approved antiviral drugs over the past 50 years},\n  journal = {Clin. Microbiol. Rev},\n  volume = {29},\n  pages = {695\u2013747},\n  date = {2016},\n  language = {}\n}\n@article{zumla2016a,\n  author = {Zumla, A.},\n  title = {Coronaviruses \u2014 drug discovery and therapeutic options},\n  journal = {Nat. Rev. Drug Discov},\n  volume = {15},\n  pages = {327\u2013347},\n  date = {2016},\n  more-authors = {true},\n  language = {}\n}\n@article{morse2020a,\n  author = {Morse, J.S. and Lalonde, T. and Shiqing, X. and Liu, W.R.},\n  title = {Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV},\n  journal = {ChemBioChem},\n  url = {https://doi.org/10.1002/cbic.202000047},\n  date = {2020},\n  language = {}\n}\n@article{de2019a,\n  author = {De Clercq, E.},\n  title = {New nucleoside analogues for the treatment of hemorrhagic fever virus infections},\n  journal = {Chem. Asian J},\n  volume = {14},\n  pages = {3962\u20133968},\n  date = {2019},\n  language = {}\n}\n@incollection{wang2019a,\n  author = {Wang, M.},\n  title = {Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus},\n  date = {2019},\n  url = {https://doi.org/10.1038/s41422-020-0282-0},\n  more-authors = {true},\n  source = {in vitro. Cell Res},\n  language = {}\n}\n@misc{holshue2020a,\n  author = {Holshue, M.L.},\n  title = {First case of 2019 novel coronavirus in the United States},\n  editor = {Med, N.Engl J.},\n  url = {https://doi.org/10.1056/NEJMoa2001191},\n  date = {2020},\n  more-authors = {true},\n  language = {}\n}\n",
        "links": [
            "https://doi.org/10.1038/"
        ],
        "pages": "149-150",
        "cited_by": 7,
        "references_ris": "TY  - JOUR\nAU  - De Clercq, E.\nAU  - Li, G.\nTI  - Approved antiviral drugs over the past 50 years\nT2  - Clin. Microbiol. Rev\nVL  - 29\nSP  - 695\nEP  - 747\nPY  - 2016\nDA  - 2016\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zumla, A.\nTI  - Coronaviruses \u2014 drug discovery and therapeutic options\nT2  - Nat. Rev. Drug Discov\nVL  - 15\nSP  - 327\nEP  - 347\nPY  - 2016\nDA  - 2016\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Morse, J.S.\nAU  - Lalonde, T.\nAU  - Shiqing, X.\nAU  - Liu, W.R.\nTI  - Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV\nT2  - ChemBioChem\nUR  - https://doi.org/10.1002/cbic.202000047\nPY  - 2020\nDA  - 2020\nLA  - \nER  - \n\nTY  - JOUR\nAU  - De Clercq, E.\nTI  - New nucleoside analogues for the treatment of hemorrhagic fever virus infections\nT2  - Chem. Asian J\nVL  - 14\nSP  - 3962\nEP  - 3968\nPY  - 2019\nDA  - 2019\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Wang, M.\nTI  - Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus\nPY  - 2019\nDA  - 2019\nUR  - https://doi.org/10.1038/s41422-020-0282-0\nC1  - true\nT2  - in vitro. Cell Res\nLA  - \nER  - \n\nTY  - GEN\nAU  - Holshue, M.L.\nTI  - First case of 2019 novel coronavirus in the United States\nA2  - Med, N.Engl J.\nUR  - https://doi.org/10.1056/NEJMoa2001191\nPY  - 2020\nDA  - 2020\nC1  - true\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "acknowledgements": [
            "We would like to thank P. Kirkpatrick for his critical comments and editorial assistance to improve this article. This work was supported by the National Nature Science Foundation of China (grant numbers 31571368, 31871324 and 81730064), the National Science and Technology Major Project (grant number 2018ZX10715004), the Natural Science Foundation of Hunan Province (grant number 2018JJ3713), the Hunan Youth Elite Project (grant number 2018RS3006) and the Project of Innovation-Driven Plan of Central South University (grant 2016CX031)."
        ],
        "disclosures": [
            "The authors declare no competing interests."
        ],
        "supplementary": [
            "<strong>Supplementary information</strong><br/><br/>Supplementary information is available for this paper at https://doi.org/ 10.1038/d41573-020-00016-0<br/><br/>150 | March 2020 | volume 19 www.nature.com/nrd"
        ],
        "funding": [
            "This work was supported by the National Nature Science Foundation of China (grant numbers 31571368, 31871324 and 81730064), the National Science and Technology Major Project (grant number 2018ZX10715004), the Natural Science Foundation of Hunan Province (grant number 2018JJ3713), the Hunan Youth Elite Project (grant number 2018RS3006) and the Project of Innovation-Driven Plan of Central South University (grant 2016CX031)"
        ],
        "data_availability": [
            "Supplementary information Supplementary information is available for this paper at https://doi.org/10.1038/d41573-020-00016-0"
        ],
        "supplementary_references": {
            "supplementary_data_references": [
                "Supplementary information"
            ],
            "supplementary_figure_references": [
                "Supplementary Table 1"
            ]
        },
        "introduction": [
            "Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.",
            "The 2019 novel coronavirus (2019-nCoV; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) has spread rapi\u00addly since its recent identification in patients with severe pneumonia in Wuhan, China. As of 10 February 2020, 2019-nCoV has been reported in 25 countries across 4 continents and >40,000 cases have been confirmed, with an estimated mortality risk of ~2%."
        ]
    },
    "structured_content": {
        "Acknowledgements": [
            "We would like to thank P. Kirkpatrick for his critical comments and editorial assistance to improve this article. This work was supported by the National Nature Science Foundation of China (grant numbers 31571368, 31871324 and 81730064), the National Science and Technology Major Project (grant number 2018ZX10715004), the Natural Science Foundation of Hunan Province (grant number 2018JJ3713), the Hunan Youth Elite Project (grant number 2018RS3006) and the Project of Innovation-Driven Plan of Central South University (grant 2016CX031).",
            "Competing interests The authors declare no competing interests.",
            "Supplementary information Supplementary information is available for this paper at https://doi.org/ 10.1038/d41573-020-00016-0"
        ]
    },
    "participants": [
        {
            "participant": "non-structural proteins",
            "number": 4,
            "context": "Similar to SARS and MERS, the 2019-nCoV genome encodes non-structural proteins (such as 3-chymotrypsin-like protease, papain-like protease, helicase, and RNA-dependent RNA polymerase), structural proteins (such as spike glycoprotein) and accessory proteins (Online Fig. 1). <mark class=\"stats\">The four non-structural proteins mentioned above are key enzymes in the viral life cycle, and the spike glycoprotein is indispensable for virus\u2013cell receptor interactions during viral entry2</mark>. These five proteins were therefore recognized as attractive targets to develop antiviral agents against SARS and MERS2"
        },
        {
            "participant": "proteins",
            "number": 5,
            "context": "The four non-structural proteins mentioned above are key enzymes in the viral life cycle, and the spike glycoprotein is indispensable for virus\u2013cell receptor interactions during viral entry2. <mark class=\"stats\">These five proteins were therefore recognized as attractive targets to develop antiviral agents against SARS and MERS2</mark>. Initial analyses of genomic sequences from 2019-nCoV indicate that the catalytic sites of the four 2019-nCoV enzymes that could represent antiviral targets are highly conserved, and share a high level of sequence similarity with the corresponding SARS and MERS enzymes[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>]"
        }
    ],
    "statistics": [],
    "keywords": [
        "recent identification",
        "treatment option",
        "Middle East respiratory syndrome",
        "ncov infection",
        "COVID-19",
        "severe acute respiratory infection",
        "ncov outbreak",
        "severe acute respiratory syndrome",
        "hepatitis B virus",
        "antiviral agent",
        "severe acute respiratory syndrome coronavirus",
        "first case",
        "hemorrhagic fever virus infection",
        "therapeutic options",
        "drug discovery",
        "respiratory syncytial virus",
        "coronavirus",
        "severe pneumonia",
        "clinical trial",
        "mortality risk",
        "possible urgent prevention",
        "hepatitis C virus",
        "antiviral drug",
        "sars cov",
        "ncov. new nucleoside analogue",
        "novel coronavirus"
    ],
    "keyword_relevance": {
        "severe acute respiratory syndrome": 0.22988505747126436,
        "Middle East respiratory syndrome": 0.1839080459770115,
        "coronavirus": 0.1724137931034483,
        "antiviral agent": 0.06896551724137931,
        "hepatitis C virus": 0.06896551724137931,
        "novel coronavirus": 0.04597701149425287,
        "hepatitis B virus": 0.034482758620689655,
        "treatment option": 0.022988505747126436,
        "respiratory syncytial virus": 0.022988505747126436,
        "clinical trial": 0.022988505747126436,
        "recent identification": 0.011494252873563218,
        "COVID-19": 0.011494252873563218,
        "severe acute respiratory infection": 0.011494252873563218,
        "severe acute respiratory syndrome coronavirus": 0.011494252873563218,
        "hemorrhagic fever virus infection": 0.011494252873563218,
        "therapeutic options": 0.011494252873563218,
        "drug discovery": 0.011494252873563218,
        "severe pneumonia": 0.011494252873563218,
        "mortality risk": 0.011494252873563218,
        "possible urgent prevention": 0.011494252873563218,
        "antiviral drug": 0.011494252873563218,
        "ncov infection": 0.0,
        "ncov outbreak": 0.0,
        "first case": 0.0,
        "sars cov": 0.0,
        "ncov. new nucleoside analogue": 0.0
    },
    "species": [],
    "summary": [
        "Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, the authors discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection ( known as COVID-19), some of which are already moving into clinical trials.",
        "Given the urgency of the 2019-nCoV outbreak, the authors focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>], based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).",
        "Favipiravir (T-705), a guanine analogue approved for influenza treatment, can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikun\u00ad gunya, norovirus and enterovirus[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>], and a recent study reported its activity against 2019-nCoV (EC50 = 61.88 \u03bcM in Vero E6 cells)[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>].",
        "Ribavirin is a guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] and whether it offers sufficient potency against 2019-nCoV is uncertain.",
        "Remdesivir has broad-spectrum activities against RNA viruses such as MERS and SARS in cell cultures and animal models, and has been tested in a clinical",
        "Galidesivir (BCX4430), an adenosine analogue that was originally developed for HCV, is currently in early-stage clinical studies evaluating its safety in healthy subjects and its efficacy against yellow fever, and has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS2.",
        "Approved protease inhibitors including disulfiram, lopinavir and ritonavir have been reported to be active against SARS and MERS.",
        "Disulfiram, an approved drug to treat alcohol dependence, has been reported to inhibit the papain-like protease of MERS and SARS in cell cultures (Supplementary Table 1), but clinical evidence is lacking.",
        "Clinical trials have been initiated to test HIV protease inhibitors such as lopinavir and ritonavir in patients infected with 2019-nCoV.",
        "Lopinavir and ritonavir were initially hypothesized to inhi\u00ad bit the 3-chymotrypsin-like protease of SARS and MERS, and appeared to be associated with improved clinical outcomes of patients with SARS in a non-randomized openlabel trial[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>].",
        "It is worth mentioning that many attempts have been made to develop host-targeted small molecules against viral infections in the past 50 years, only maraviroc has gained approval by the FDA, for HIV treatment[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
        "The reported EC50 and IC50 values of existing MERS and/or SARS inhibitors are mostly in the micromolar range, and further optimization of their activities against 2019-nCoV is probably needed before agents would be ready for clinical evaluation."
    ],
    "structured_summary": {
        "Introduction": [
            "Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, the authors discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection ( known as COVID-19), some of which are already moving into clinical trials.",
            "Given the urgency of the 2019-nCoV outbreak, the authors focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>], based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)."
        ],
        "Results": [
            "Favipiravir (T-705), a guanine analogue approved for influenza treatment, can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikun\u00ad gunya, norovirus and enterovirus[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>], and a recent study reported its activity against 2019-nCoV (EC50 = 61.88 \u03bcM in Vero E6 cells)[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>].",
            "Ribavirin is a guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] and whether it offers sufficient potency against 2019-nCoV is uncertain.",
            "Remdesivir has broad-spectrum activities against RNA viruses such as MERS and SARS in cell cultures and animal models, and has been tested in a clinical",
            "Galidesivir (BCX4430), an adenosine analogue that was originally developed for HCV, is currently in early-stage clinical studies evaluating its safety in healthy subjects and its efficacy against yellow fever, and has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS2.",
            "Approved protease inhibitors including disulfiram, lopinavir and ritonavir have been reported to be active against SARS and MERS.",
            "Disulfiram, an approved drug to treat alcohol dependence, has been reported to inhibit the papain-like protease of MERS and SARS in cell cultures (Supplementary Table 1), but clinical evidence is lacking.",
            "Clinical trials have been initiated to test HIV protease inhibitors such as lopinavir and ritonavir in patients infected with 2019-nCoV.",
            "Lopinavir and ritonavir were initially hypothesized to inhi\u00ad bit the 3-chymotrypsin-like protease of SARS and MERS, and appeared to be associated with improved clinical outcomes of patients with SARS in a non-randomized openlabel trial[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>]."
        ],
        "Conclusion": [
            "It is worth mentioning that many attempts have been made to develop host-targeted small molecules against viral infections in the past 50 years, only maraviroc has gained approval by the FDA, for HIV treatment[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
            "The reported EC50 and IC50 values of existing MERS and/or SARS inhibitors are mostly in the micromolar range, and further optimization of their activities against 2019-nCoV is probably needed before agents would be ready for clinical evaluation."
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "de_Clercq_2016_a",
            "entry": "1. De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016"
        },
        {
            "id": "2",
            "alt_id": "Zumla_2016_a",
            "entry": "2. Zumla, A. et al. Coronaviruses \u2014 drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327\u2013347 (2016).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zumla%2C%20A.%20Coronaviruses%20%E2%80%94%20drug%20discovery%20and%20therapeutic%20options%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zumla%2C%20A.%20Coronaviruses%20%E2%80%94%20drug%20discovery%20and%20therapeutic%20options%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zumla%2C%20A.%20Coronaviruses%20%E2%80%94%20drug%20discovery%20and%20therapeutic%20options%202016"
        },
        {
            "id": "3",
            "alt_id": "Morse_et+al_2020_a",
            "entry": "3. Morse, J. S., Lalonde, T., Shiqing, X. & Liu, W. R. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem https://doi.org/10.1002/cbic.202000047 (2020).",
            "crossref": "https://dx.doi.org/10.1002/cbic.202000047",
            "scite": "https://scite.ai/reports/10.1002/cbic.202000047",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1002/cbic.202000047"
        },
        {
            "id": "4",
            "alt_id": "de_Clercq_2019_a",
            "entry": "4. De Clercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem. Asian J. 14, 3962\u20133968 (2019).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=De%20Clercq%2C%20E.%20New%20nucleoside%20analogues%20for%20the%20treatment%20of%20hemorrhagic%20fever%20virus%20infections%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=De%20Clercq%2C%20E.%20New%20nucleoside%20analogues%20for%20the%20treatment%20of%20hemorrhagic%20fever%20virus%20infections%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=De%20Clercq%2C%20E.%20New%20nucleoside%20analogues%20for%20the%20treatment%20of%20hemorrhagic%20fever%20virus%20infections%202019"
        },
        {
            "id": "5",
            "alt_id": "Wang_2019_a",
            "entry": "5. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. https://doi.org/10.1038/s41422-020-0282-0 (2020).",
            "crossref": "https://dx.doi.org/10.1038/s41422-020-0282-0",
            "scite": "https://scite.ai/reports/10.1038/s41422-020-0282-0",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/s41422-020-0282-0"
        },
        {
            "id": "6",
            "alt_id": "Holshue_2020_a",
            "entry": "6. Holshue, M. L. et al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. https://doi.org/10.1056/ NEJMoa2001191 (2020).",
            "url": "https://doi.org/10.1056/NEJMoa2001191"
        }
    ],
    "facts": [
        "some of which are already moving into clinical trials",
        "in development for treating infections caused by HIV",
        "on thera\u00adpeutic experience with two other infections caused by human coronaviruses",
        "a guanine analogue approved for influenza treatment",
        "a guanine derivative approved for treating HCV",
        "respiratory syncytial virus that has been evaluated in patients with SARS",
        "an adenosine analogue that was originally developed for HCV",
        "lopinavir and ritonavir have been reported to be active against SARS",
        "worth mentioning that many attempts have been made to develop host-targeted small molecules",
        "before agents would be ready for clinical evaluation"
    ],
    "claims": [
        "Given the urgency of the 2019-nCoV outbreak, we focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza1, based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"
    ],
    "findings": [],
    "processes": [],
    "key_statements": [
        "Given the urgency of the 2019-nCoV outbreak, we focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>], based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)",
        "Favipiravir (T-705), a guanine analogue approved for influenza treatment, can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikun\u00ad gunya, norovirus and enterovirus[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>], and a recent study reported its activity against 2019-nCoV (EC50 = 61.88 \u03bcM in Vero E6 cells)[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>]",
        "Ribavirin is a guanine derivative approved for treating hepatitis C virus and respiratory syncytial virus (RSV) that has been evaluated in patients with severe acute respiratory syndrome and Middle East respiratory syndrome, but its side effects such as anaemia may be severe at high doses[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] and whether it offers sufficient potency against 2019-nCoV is uncertain",
        "Galidesivir (BCX4430), an adenosine analogue that was originally developed for hepatitis C virus, is currently in early-stage clinical studies evaluating its safety in healthy subjects and its efficacy against yellow fever, and has shown antiviral activities in preclinical studies against many RNA viruses, including severe acute respiratory syndrome and MERS2",
        "Approved protease inhibitors including disulfiram, lopinavir and ritonavir have been reported to be active against severe acute respiratory syndrome and Middle East respiratory syndrome",
        "The reported EC50 and IC50 values of existing Middle East respiratory syndrome and/or severe acute respiratory syndrome inhibitors are mostly in the micromolar range, and further optimization of their activities against 2019-nCoV is probably needed before agents would be ready for clinical evaluation"
    ],
    "top_statements": [
        "Therapeutic options in response to the 2019-nCoV outbreak are urgently needed",
        "Given the urgency of the 2019-nCoV outbreak, we focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>], based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)",
        "Ribavirin is a guanine derivative approved for treating hepatitis C virus and respiratory syncytial virus (RSV) that has been evaluated in patients with severe acute respiratory syndrome and Middle East respiratory syndrome, but its side effects such as anaemia may be severe at high doses[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] and whether it offers sufficient potency against 2019-nCoV is uncertain",
        "Galidesivir (BCX4430), an adenosine analogue that was originally developed for hepatitis C virus, is currently in early-stage clinical studies evaluating its safety in healthy subjects and its efficacy against yellow fever, and has shown antiviral activities in preclinical studies against many RNA viruses, including severe acute respiratory syndrome and MERS2",
        "Approved protease inhibitors including disulfiram, lopinavir and ritonavir have been reported to be active against severe acute respiratory syndrome and Middle East respiratory syndrome",
        "The reported EC50 and IC50 values of existing Middle East respiratory syndrome and/or severe acute respiratory syndrome inhibitors are mostly in the micromolar range, and further optimization of their activities against 2019-nCoV is probably needed before agents would be ready for clinical evaluation"
    ],
    "headline": "Given the urgency of the 2019-nCoV outbreak, we focus here on the potential to repurpose existing antiviral agents approved or in development for treating infections caused by HIV, hepatitis B virus, hepatitis C virus and influenza1, based on thera\u00adpeutic experience with two other infections caused by human coronaviruses: severe acute respiratory syndrome and Middle East respiratory syndrome",
    "contexts": [],
    "abbreviations": {
        "HBV": "hepatitis B virus",
        "HCV": "hepatitis C virus",
        "SARS": "severe acute respiratory syndrome",
        "MERS": "Middle East respiratory syndrome",
        "RSV": "respiratory syncytial virus"
    }
}
